Cover Image
市場調查報告書

出血性疾病治療藥的全球市場 - 2021年:種類 (A型血友病、B型血友病、vWD)、藥物 (血漿原來因素、重組的凝固、去氨加壓素,抗線溶藥)

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Factor, Recombinant Coagulation, Desmopressin, Antibrinolytics), Geography - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 363185
出版日期 內容資訊 英文 166 Pages
訂單完成後即時交付
價格
Back to Top
出血性疾病治療藥的全球市場 - 2021年:種類 (A型血友病、B型血友病、vWD)、藥物 (血漿原來因素、重組的凝固、去氨加壓素,抗線溶藥) Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Factor, Recombinant Coagulation, Desmopressin, Antibrinolytics), Geography - Global Forecast to 2021
出版日期: 2016年07月11日 內容資訊: 英文 166 Pages
簡介

全球出血性疾病 (出血障礙) 治療藥市場,預計從2016年的103億3000萬美元,擴大到2021年到150億9000萬美元。市場,預計2016年∼2021年以7.9%的年複合成長率成長。

本報告提供全球出血性疾病治療藥市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 市場威脅

第5章 全球出血性疾病治療藥市場:各類型

  • 簡介
  • A型血友病
  • B型血友病
  • 類血友病病 (vWD)
  • 其他

第6章 全球出血性疾病治療藥市場:各藥物分類

  • 簡介
  • 血漿原來凝血因子
  • 重組的凝血因子
  • 其他

第7章 全球出血性疾病治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 競爭情形

  • 市場佔有率分析
  • 主要的成長策略

第9章 企業簡介

  • BAXALTA (現在:SHIRE)
  • BAYER PHARMACEUTICALS
  • NOVO NORDISK A/S
  • PFIZER INC.
  • BIOGEN IDEC
  • CSL BEHRING
  • GRIFOLS
  • OCTAPHARMA

第10章 附錄

目錄
Product Code: PH 4424

The global bleeding disorders treatment market is projected to reach USD 15.09 billion by 2021 from USD 10.33 billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The increasing acceptance for prophylaxis treatment among all age groups, rising volume of diagnosed patients, and increasing R&D investments for the development of hemophilia products are driving the global market for bleeding disorders treatment. On the other hand, high costs for bleeding disorder treatment products is a major factor expected to restrain the growth of this market during the forecast period.

The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products

The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.

Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.

The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the bleeding disorders treatment market. The report analyses the bleeding disorders treatment market by type, drug class, and geography/ region.
  • Product Development/Innovation: Detailed insights on the pipeline products, R&D activities, and new product launches in the bleeding disorders treatment market.
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the bleeding disorders treatment market.
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various bleeding disorder treatment market products across geographies.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bleeding disorders treatment market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS
  • 1.6. ASSUMPTIONS & LIMITATIONS

2. RESEARCH METHODOLOGY

  • 2.1. INTRODUCTION
  • 2.2. SECONDARY DATA
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
  • 2.3. PRIMARY DATA
    • 2.3.1. BREAKDOWN OF PRIMARIES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS
  • 2.4. MARKET SIZE ESTIMATION
    • 2.4.1. BOTTOM-UP APPROACH
    • 2.4.2. TOP-DOWN APPROACH
  • 2.5. MARKET BREAKDOWN AND DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. MARKET DYNAMICS
  • 3.3. MARKET ESTIMATION

4. MARKET DYNAMICS

  • 4.1. MARKET DRIVERS
    • 4.1.1. RISING R&D INVESTMENT FOR DEVELOPMENT OF HEMOPHILIA PRODUCTS
    • 4.1.2. INCREASING PREFERENCE FOR PROPHYLACTIC TREATMENT
    • 4.1.3. INCREASING NUMBER OF DIAGNOSED HEMOPHILIA PATIENTS
    • 4.1.4. INCREASING HEALTHCARE EXPENDITURE
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. HIGH COST OF HEMOPHILIA DRUGS
    • 4.2.2. INSUFFICIENT REIMBURSEMENT
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. LOCAL PARTNERSHIPS IN PHARMAEMERGING COUNTRIES
    • 4.3.2. RISING DISPOSABLE INCOME AND IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING NATIONS
    • 4.3.3. GROWING BIOSIMILAR PRODUCTS MARKET
  • 4.4. MARKET THREATS
    • 4.4.1. HIGH ENTRY BARRIERS CREATED BY LOCAL GOVERNMENT IN CERTAIN COUNTRIES
    • 4.4.2. LOW SWITCH RATE FOR HEMOPHILIA PRODUCTS
    • 4.4.3. HIGH COMPETITION FROM ESTABLISHED PLAYERS

5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE

  • 5.1. INTRODUCTION
  • 5.2. HEMOPHILIA A
  • 5.3. HEMOPHILIA B
  • 5.4. VON WILLEBRAND DISEASE (vWD)
  • 5.5. OTHERS

6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY DRUG CLASS

  • 6.1. INTRODUCTION
  • 6.2. PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET
  • 6.3. GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET
  • 6.4. GLOBAL OTHERS BLEEDING DISORDERS TREATMENT MARKET

7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY

  • 7.1. INTRODUCTION
  • 7.2. NORTH AMERICA
  • 7.3. EUROPE
  • 7.4. ASIA-PACIFIC
  • 7.5. REST OF THE WORLD (ROW)

8. COMPETITIVE LANDSCAPE

  • 8.1. MARKET SHARE ANALYSIS, BY KEY PLAYERS
  • 8.2. KEY GROWTH STRATEGIES, 2013-2016
  • 8.3. KEY GROWTH STRATEGIES: NEW PRODUCT APPROVAL/ LAUNCH, 2013-2016
  • 8.4. KEY GROWTH STRATEGIES: AGREEMENTS, 2013-2016
  • 8.5. KEY GROWTH STRATEGIES: M&A, 2013-2016
  • 8.6. KEY GROWTH STRATEGIES: OTHER STRATEGIES, 2013-2016

9. COMPANY PROFILES

  • 9.1. BAXALTA (NOW SHIRE)
  • 9.2. BAYER PHARMACEUTICALS
  • 9.3. NOVO NORDISK A/S
  • 9.4. PFIZER INC.
  • 9.5. BIOGEN IDEC
  • 9.6. CSL BEHRING
  • 9.7. GRIFOLS
  • 9.8. OCTAPHARMA

10. APPENDIX

  • 10.1. KEY INDUSTRY INSIGHTS
  • 10.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 10.3. INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
  • 10.4. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: PIPELINE ANALYSIS (RECENTLY APPROVED)
  • TABLE 2: PIPELINE ANALYSIS (TO BE APPROVED)
  • TABLE 3: GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE, 2014 - 2021 (USD MILLION)
  • TABLE 4: HEMOPHILIA A TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 5: HEMOPHILIA A TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 6: HEMOPHILIA B TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 7: HEMOPHILIA B TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 8: vWD TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 9: OTHERS TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 10: GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 11: GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 12: GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
  • TABLE 13: GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 14: GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
  • TABLE 15: OTHER BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
  • TABLE 16: GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2014 - 2021 (USD MILLION)
  • TABLE 17: NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 18: NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
  • TABLE 19: NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 20: NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 21: EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 22: EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
  • TABLE 23: EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 24: EUROPE: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 25: ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 26: ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
  • TABLE 27: ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 28: ASIA-PACIFI:C BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 29: ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
  • TABLE 30: ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
  • TABLE 31: ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
  • TABLE 32: ROW: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • TABLE 33: NEW PRODUCT APPROVAL/ LAUNCH, 2013 - 2016
  • TABLE 34: AGREEMENTS, 2013 - 2016
  • TABLE 35: M&A, 2013 - 2016
  • TABLE 36: OTHER STATEGIES, 2013 - 2016

LIST OF FIGURES

  • FIGURE 1: GLOBAL HEMOPHILIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, REGION
  • FIGURE 4: MARKET SIZE ESTIMATION DIAGRAM
  • FIGURE 5: MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: COMPARATIVE ANALYSIS, GLOBAL MARKET BY TYPE 2015 VS 2021
  • FIGURE 7: COMPARATIVE ANALYSIS, GLOBAL MARKET BY DRUG CLASS 2015 VS 2021
  • FIGURE 8: GLOBAL SNAPSHOT: BLEEDING DISORDERS TREATMENT MARKET SCENARIO, 2015
  • FIGURE 9: IMPACT ANALYSIS : DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
  • FIGURE 10: BLEEDING DISORDERS TREATMENT MARKET : DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
  • FIGURE 11: MARKET ATTRACTIVENESS, BY TYPE
  • FIGURE 12: MARKET ATTRACTIVENESS, BY DRUG CLASS
  • FIGURE 13: GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2015 (USD MILLION)
  • FIGURE 14: GLOBAL BLEEDING DISORDERS TREATMENT MARKET SCENARIO, BY GEOGRAPHY, 2015
  • FIGURE 15: NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
  • FIGURE 16: EUROPE: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
  • FIGURE 17: ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
  • FIGURE 18: ROW: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
  • FIGURE 19: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
  • FIGURE 20: COMPETITIVE LANDSCAPE: KEY DEVELOPMENTS
Back to Top